News

Pelage Pharmaceuticals Advances Clinical Program with First Patients Dosed in Phase 2 Study for Hair Loss

Pelage Pharmaceuticals Advances Clinical Program with First Patients Dosed in Phase 2 Study for Hair Loss and GV-Led $14M Series A-1 NEWS PROVIDED BY Pelage Pharmaceuticals 

Aug 13, 2024, 08:00 ET 

  • Inclusive trial recruiting women and men with androgenetic alopecia to evaluate safety and preliminary efficacy of PP405, a topical treatment designed to reactivate dormant hair follicle stem cells